• Ashuin Kammar-García, José de J Vidal-Mayo, Juan M Vera-Zertuche, Martín Lazcano-Hernández, Obdulia Vera-López, Orietta Segura-Badilla, Patricia Aguilar-Alonso, and Addi R Navarro-Cruz.
• Emergency Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
• Rev Invest Clin. 2020 Jan 1; 72 (3): 151-158.

BackgroundThe coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world.ObjectiveThe objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population.Materials And MethodsWe analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient.ResultsThe patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities.ConclusionsThe number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients.Copyright: © 2020 Permanyer.

58 keywords...

hide…